10-Q: Quarterly report
10-Q: Q2 2024 Earnings Report
BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock
BiomX Inc. Receives Notice of Non-Compliance With NYSE American Continued Listing Standards
10-Q: Q1 2024 Earnings Report
BiomX Announces Compliance With NYSE Guidelines on Audit Opinion Disclosure
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
BiomX Announces Entry Into Merger Agreement With Adaptive Phage Therapeutics and Concurrent $50 Million Financing
No Data
No Data